In addition, the results of a comparative trial of MAPCs for stroke in splenectomized and sham splenectomized mice also demonstrated that MAPCs could inhibit expansion of the infarct volume through a non-spleen-mediated mechanism, but the MAPC-induced IL-10 production after tMCAO was still dependent on an intact spleen. This evidence concerns the gene IL10 and Stroke.